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Angelica Romero
BIOL 488 – Senior Capstone
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Background Information/ Introduction

Figure 1. Alzheimer’s Disease Facts
Alzheimer’s Disease affects 1 in 3 seniors,
and is the 6th leading cause of death in the
United States.

Specific Aim: My specific aim is
to modify Amyloid-Beta 40
(Aβ40) and Amyloid-Beta 42
(Aβ42). This is so the proteins
will not interfere with neuronal
signaling. This modification
should act as a therapy for
patients.

• Alzheimer Disease is the most
common cause of Dementia,
which slowly deteriorates the
brain.
• Tangles and Plaques are two
major components in the
process of Alzheimer’s.
• Plaques and Tangles interfere
with neuron signaling in the
brain, which can lead to memory
impairment.
• There are two specific groups of
AD. Familial, which is early onset
and Sporadic, which is late
onset.
• Amyloid-Beta 40 (Aβ40) and
Amyloid-Beta 42 (Aβ42) are
responsible for
neurodegeneration and agedependent learning defects.

Figure 2. Impacts on the brain
On the left side, this figure displays the
atrophic affects of Alzheimer’s Disease. The
right side displays a healthy brain.

Proposed Methodology
Neuronal Cultures

Trafficking Assay

Preparations for
Amyloid Oligomers

Abeta Binding
Assay

Synapse Counting
Assay

Statistical Assay

• Collect rat embryos and extract their Hippocampus and Cortical tissue. Add 2.5%
Trypsin to dissociate the cells. Place cells in 384-poly D-Lysine coated plates with
Neurobasal Media, Glutamax, and antibiotics

Experimental Results
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Figure 3. Hippocampal/cortical cultures immunofluorescent labeling.
A. Labeled MAP2 neurons. B. Labeled DAPI nuclei. C. Labeled GFAP glia and Nuclei. D.
This image displays the merging parts of all three images. The percentage of neurons
was 26.0 ± 1.1% in the cultures. This was based on the untreated control wells. (Izzo
2014) The primary rat neurons can replicate the electrophysiological state-dependent
signaling.
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Figure 4. Plaques and Tangles
These illustrations display the process of how plaques and tangles function in the brain. A.
The top picture shows where plaques are located on the nueron. The bottom picture shows
how tau are attached to the microtubules. B. This illustration shows the atrophic affects of
the brain from plaques and tangles.

Discussion/ Conclusions

• For Synthetic Abeta 40/42 oligomer preparation, add oligomers an hour prior to the
compounds. For 15 minutes, fix the cells with 0.5% of Triton X-1003, .75% formaldehyde
and block with 5% goat serum. Incubate with the primary antibodies for Synaptophysin1, glial fibrillary acidic protein and Abeta, MAP-2.

Potential Pitfalls:
• Creating a therapy could cause issues with patients.
• There could possibly be failure to provide therapeutic benefits for patients with
Alzheimer’s Disease.
• There could also be a failure in therapy if the patient has undergone too much
neuronal loss.
Potential Conclusions:
• The symptoms of neurodegeneration could decrease with modifications done to the
Amyloid Beta-40 and 42 proteins.
• This could serve as a therapy for AD patients and save people from losing their
memory entirely.
• A cure still hasn’t been found for Alzheimer’s, so it’s important to continue
researching this insufferable disease.

• Before adding 6 mM of synthetic Abeta 40/42 oligomers, treat cultures with
compounds. Then, incubate for 24 hours. Use the ThermoFisher/Cellomics Neuronal
Profiling bio application to count the synaptophysin-immunopositive puncta .
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